Literature DB >> 12434420

Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.

Margaret J Currie1, Sarah P Gunningham, Kevin Turner, Cheng Han, Prudence A E Scott, Bridget A Robinson, Wen Chong, Adrian L Harris, Stephen B Fox.   

Abstract

Angiogenesis is essential for tumour growth and metastasis, and is co-ordinated by several classes of angiogenic factors. To determine the significance and regulation of the angiopoietin (Ang) pathway in highly vascular human renal cell carcinomas (RCCs), this study has investigated the expression of the Ang-1, Ang-2, Ang-4, and Tie2 genes in a series of normal (n = 26) and neoplastic (n = 45; clear cell n = 35, papillary n = 10) human kidney tissues, examined the pattern of Ang-2 and Tie2 protein expression, and correlated expression with clinicopathological variables. The effect of the von Hippel-Lindau (VHL) gene and hypoxia in the renal cell lines RCC786-0 and RCC4 has also been investigated. Ang-1, Ang-2 and Tie2, but not Ang-4 mRNA, were detected in normal and tumour samples. A significant increase in Ang-2 (p < 0.001) and a decrease in Tie2 receptor mRNA (p = 0.001) were observed, but no significant difference was observed in Ang-1 mRNA abundance between normal kidney and RCC (p = 0.37). Immunohistochemistry for Ang-2 showed strong expression in vascular endothelium and weak expression in tumour cells, whereas Tie2 was expressed exclusively on endothelium. Tie2 gene expression was positively correlated with Ang-2 expression in cancers (p = 0.001) and showed a borderline significant association with Ang-1 (p = 0.06), but there was no significant relationship between Ang-1 and Ang-2 (p = 0.69). No significant relationships were observed in clear cell carcinomas between Ang-1, Ang-2 and Tie2 mRNA abundance and patient sex, patient age, or tumour size (p > 0.05). However, there was significantly greater Ang-1 (p = 0.02), Ang-2 (p = 0.03), and Tie2 (p = 0.04) mRNA abundance in clear cell than in chromophil RCCs. Ang-2 gene expression was down-regulated by hypoxia in VHL wild-type RCC786-0 and RCC4 transfectants (p = 0.0002 and p = 0.04, respectively), mirroring the low expression in human tumour cells. These data suggest that it is endothelial induction of Ang-2 in tumours that regulates vessel stability and supports targeting Tie2 as an effective novel anti-angiogenic therapy in clear cell RCCs. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12434420     DOI: 10.1002/path.1228

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  14 in total

Review 1.  How far is the horizon? From current targets to future drugs in advanced renal cancer.

Authors:  Stephan Kruck; Axel S Merseburger; Arnulf Stenzl; Jens Bedke
Journal:  World J Urol       Date:  2013-05-09       Impact factor: 4.226

Review 2.  Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.

Authors:  I Duran; J Lambea; P Maroto; J L González-Larriba; Luis Flores; S Granados-Principal; M Graupera; B Sáez; A Vivancos; O Casanovas
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

3.  Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment.

Authors:  Melissa K Brunckhorst; Yin Xu; Rong Lu; Qin Yu
Journal:  Am J Pathol       Date:  2014-08       Impact factor: 4.307

4.  AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.

Authors:  Brian Rini; Cezary Szczylik; Nizar M Tannir; Piotr Koralewski; Piotr Tomczak; Andrzej Deptala; Luc Y Dirix; Mayer Fishman; Rodryg Ramlau; Alain Ravaud; Wojciech Rogowski; Karolyn Kracht; Yu-Nien Sun; Michael B Bass; Markus Puhlmann; Bernard Escudier
Journal:  Cancer       Date:  2012-06-12       Impact factor: 6.860

Review 5.  Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.

Authors:  Sumanta Kumar Pal; Stephen Williams; David Y Josephson; Courtney Carmichael; Nicholas J Vogelzang; David I Quinn
Journal:  Mol Cancer Ther       Date:  2012-02-17       Impact factor: 6.261

Review 6.  New insights into the biology of renal cell carcinoma.

Authors:  Lianjie Li; William G Kaelin
Journal:  Hematol Oncol Clin North Am       Date:  2011-08       Impact factor: 3.722

7.  A Comprehensive Study of Progressive Cytogenetic Alterations in Clear Cell Renal Cell Carcinoma and a New Model for ccRCC Tumorigenesis and Progression.

Authors:  Zhongfa Zhang; Bill Wondergem; Karl Dykema
Journal:  Adv Bioinformatics       Date:  2010-07-05

8.  Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma.

Authors:  K Sugimachi; S Tanaka; K Taguchi; S Aishima; M Shimada; M Tsuneyoshi
Journal:  J Clin Pathol       Date:  2003-11       Impact factor: 3.411

9.  Angiopoietins lack of prognostic significance in ductal mammary carcinoma.

Authors:  Khaled A Rmali; Gareth Watkins; Antonio Douglas-Jones; Robert E Mansel; Wen G Jiang
Journal:  Int Semin Surg Oncol       Date:  2007-03-23

10.  Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.

Authors:  Bishoy A Gayed; Jessica Gillen; Alana Christie; Samuel Peña-Llopis; Xian-Jin Xie; Jingsheng Yan; Jose A Karam; Ganesh Raj; Arthur I Sagalowsky; Yair Lotan; Vitaly Margulis; James Brugarolas
Journal:  BMC Urol       Date:  2015-04-03       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.